Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.32%AUDUSD-1.14%GBPCHF+1.00%GBPCAD+0.83%USDCHF+0.80%AUDJPY-0.78%EURGBP-0.67%EURAUD+0.66%USDCAD+0.65%GBPNZD+0.65%AUDNZD-0.65%USDTHB+0.60%GBPJPY+0.56%AUDCAD-0.51%EURUSD-0.50%NZDUSD-0.49%GBPTRY+0.41%CHFJPY-0.38%USDJPY+0.38%AUDCHF-0.37%PLNJPY+0.34%GBPHKD+0.32%NZDCHF+0.31%EURCHF+0.30%NOKJPY+0.29%GBPMXN-0.28%USDTRY+0.28%CADJPY-0.26%SGDJPY+0.26%GBPZAR+0.18%GBPUSD+0.18%EURZAR+0.17%NZDCAD+0.16%USDILS+0.16%USDCNH-0.16%EURCAD+0.15%CADCHF+0.15%USDZAR+0.14%EURJPY-0.12%NZDMXN+0.12%CHFSGD+0.11%NZDJPY-0.09%USDMXN+0.09%CHFNOK+0.09%EURSGD+0.07%EURCNH+0.07%NZDSGD+0.07%GBPSGD+0.07%AUDDKK-0.06%EURNOK+0.06%USDDKK-0.05%CHFSEK+0.04%USDSEK-0.04%USDPLN-0.04%USDCOP-0.04%USDHKD+0.04%EURCZK-0.03%USDSGD+0.03%EURHKD+0.03%AUDSGD+0.02%EURNZD+0.01%USDNOK+0.01%EURSEK+0.01%AUDNOK0.00%EURDKK0.00%EURPLN0.00%XPTUSD-0.91%HG1-0.56%GAGUSD-0.46%XAGUSD-0.46%W1+0.39%GAUUSD-0.33%XAUUSD-0.33%UKOIL+0.28%C1+0.23%XNGUSD+0.13%USOIL+0.12%S1-0.10%BTCUSD-0.17%ETHUSD+7.44%USDTUSD-0.02%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.04%ZECUSDT+0.46%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.68%XLMUSD+2.39%BCHUSDT-0.29%UNIUSD-0.38%LTCUSD+0.07%HBARUSDT+1.48%SUIUSD+1.88%TONUSD+15.77%TAOUSDT+0.03%AAVEUSD-3.57%DOTUSDT+2.95%ICPUSDT-3.29%ONDOUSDT+0.37%WLDUSDT+10.51%ARBUSDT-0.49%JUPUSDT-0.50%ATOMUSDT+1.16%INJUSDT-2.54%STXUSDT+19.59%FETUSDT+3.82%SEIUSDT+0.33%PYTHUSDT-2.59%TIAUSDT-0.29%IMXUSDT+0.97%GRTUSDT+0.16%OPUSDT+1.31%WIFUSDT+3.04%IOTAUSDT+3.58%POLUSDT-4.29%AXSUSDT+0.85%FARTCOINUSDT-0.55%EOSUSDT+4.55%DYDXUSDT+3.91%GALAUSDT+5.20%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.32%AUDUSD-1.14%GBPCHF+1.00%GBPCAD+0.83%USDCHF+0.80%AUDJPY-0.78%EURGBP-0.67%EURAUD+0.66%USDCAD+0.65%GBPNZD+0.65%AUDNZD-0.65%USDTHB+0.60%GBPJPY+0.56%AUDCAD-0.51%EURUSD-0.50%NZDUSD-0.49%GBPTRY+0.41%CHFJPY-0.38%USDJPY+0.38%AUDCHF-0.37%PLNJPY+0.34%GBPHKD+0.32%NZDCHF+0.31%EURCHF+0.30%NOKJPY+0.29%GBPMXN-0.28%USDTRY+0.28%CADJPY-0.26%SGDJPY+0.26%GBPZAR+0.18%GBPUSD+0.18%EURZAR+0.17%NZDCAD+0.16%USDILS+0.16%USDCNH-0.16%EURCAD+0.15%CADCHF+0.15%USDZAR+0.14%EURJPY-0.12%NZDMXN+0.12%CHFSGD+0.11%NZDJPY-0.09%USDMXN+0.09%CHFNOK+0.09%EURSGD+0.07%EURCNH+0.07%NZDSGD+0.07%GBPSGD+0.07%AUDDKK-0.06%EURNOK+0.06%USDDKK-0.05%CHFSEK+0.04%USDSEK-0.04%USDPLN-0.04%USDCOP-0.04%USDHKD+0.04%EURCZK-0.03%USDSGD+0.03%EURHKD+0.03%AUDSGD+0.02%EURNZD+0.01%USDNOK+0.01%EURSEK+0.01%AUDNOK0.00%EURDKK0.00%EURPLN0.00%XPTUSD-0.91%HG1-0.56%GAGUSD-0.46%XAGUSD-0.46%W1+0.39%GAUUSD-0.33%XAUUSD-0.33%UKOIL+0.28%C1+0.23%XNGUSD+0.13%USOIL+0.12%S1-0.10%BTCUSD-0.17%ETHUSD+7.44%USDTUSD-0.02%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.04%ZECUSDT+0.46%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.68%XLMUSD+2.39%BCHUSDT-0.29%UNIUSD-0.38%LTCUSD+0.07%HBARUSDT+1.48%SUIUSD+1.88%TONUSD+15.77%TAOUSDT+0.03%AAVEUSD-3.57%DOTUSDT+2.95%ICPUSDT-3.29%ONDOUSDT+0.37%WLDUSDT+10.51%ARBUSDT-0.49%JUPUSDT-0.50%ATOMUSDT+1.16%INJUSDT-2.54%STXUSDT+19.59%FETUSDT+3.82%SEIUSDT+0.33%PYTHUSDT-2.59%TIAUSDT-0.29%IMXUSDT+0.97%GRTUSDT+0.16%OPUSDT+1.31%WIFUSDT+3.04%IOTAUSDT+3.58%POLUSDT-4.29%AXSUSDT+0.85%FARTCOINUSDT-0.55%EOSUSDT+4.55%DYDXUSDT+3.91%GALAUSDT+5.20%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%
AT

Axsome Therapeutics, Inc. (AXSM)

NASDAQ • Healthcare

$184.39
-$1.75 (-0.9%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$186.51
Day Range$184.25 - $188
Avg. Volume (3M)698.9K
Market Cap$9.4B
52 Week Range
$117.3$260.19
Next EarningsIn 32 daysNov 2, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$218.3M100%
Gross Profitminus cost of goods$204.8M94%

In plain terms: out of every $100 in revenue, Axsome Therapeutics, Inc. currently loses $23.

Fundamentals & Financials

Revenue (TTM)
$776.5M
Net Income (TTM)
-$191.6M
EPS (TTM)
-$3.75
ROA (TTM)
-25.17%
Current Ratio
1.43

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-1.4%Q1 2026-$0.71
-48.2%Q2 2026-$1.26
-11.0%Q3 2026-$0.99
Next

Nov 2

in 32 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -11.0%

Axsome Therapeutics trailed consensus on both the top and bottom line in the second fiscal quarter of 2026, reported August 10, 2026, even as revenue rose 45.5% to about $218.4 million from roughly $150.0 million a year ago. Revenue of $218.4 million trailed the $221.1 million estimate (-1.2%), and EPS of -$0.99 trailed the -$0.89 estimate (-11%), down from -$0.92 a year earlier. Profitability remained characterized by very high gross margin of ~94%, while operating margin was -22.7% alongside an operating loss of roughly $49.6 million. The quarter’s net loss widened to about $51.3 million, representing a -7.0% year-over-year change from roughly $48.0 million. Cash generation was also negative, with negative operating cash flow of around $33.0 million. For the next period, consensus calls for EPS of USD -0.49 on revenue of USD 258.1 million.

View full earnings history

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a Biotechnology company listed on the NASDAQ under AXSM that develops and commercializes central nervous system therapies in the United States. The company generated $638.5 million in revenue in FY2025 and focuses on prescription medicines and late-stage development candidates for neurologic and psychiatric conditions.

Name
Axsome Therapeutics, Inc.
CEO
Herriot Tabuteau
Website
www.axsome.com
Industry
Healthcare
Year Founded
2012
Employees
1,346

Today's Snapshot

AI-generated

AXSM closed 0.9% lower at 184.39, in line with a weaker sector.

Trading Volume

Above 10d avg 776.1K

944.4K

vs S&P 500 Today

Underperforming Market

-1.13%

Updated: September 30, 2026 at 20:14 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
AXSM exhibits clear downside pressure with momentum and trend indicators aligned for a strong sell stance. The MACD and CCI are deeply negative and short-term momentum is weakening, while the stock trades below its short-, medium- and 200-day moving averages, reinforcing broad bearish structure. ADX shows a modest trend strength and ATR implies average intraday volatility near single-digit dollars, and on balance the volume metric is signaling distribution. Bollinger measures imply price is near the lower band, underlining oversold internal readings. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$192.25 - $210.59
    Sell
  • RSI (14)31.44
    Neutral
  • Stochastic %K (14, 3, 3)8.42
    Buy
  • MACD Level (12, 26)-6.37
    Sell

Peers & Related Assets

JAZZJazz Pharmaceuticals plc
$231.52-0.4%
ARWRArrowhead Pharmaceuticals, Inc.
$65.45-1.2%
NUVLNuvalent, Inc.
$123.960.0%
PCVXVaxcyte, Inc.
$56.9+0.4%
CYTKCytokinetics, Incorporated
$65.91+0.4%
RYTMRhythm Pharmaceuticals, Inc.
$95.22-0.5%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.